- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Cubist Pharmaceuticals Inc
Add to PortfolioCBST:US
40.5400 USD 0.6700 1.68%As of 16:30:00 ET on 05/29/2012.
Snapshot for Cubist Pharmaceuticals Inc (CBST)
| Open: | 40.3100 | Day's Range: | 39.6000 - 40.7100 | Volume: | 819,879 | Bid: | 40.5400 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 39.8700 | 52wk Range: | 28.8200 - 44.9500 | 1-Yr Rtn: | +5.88% | Ask: | 40.5500 |
Key Statistics for CBST
| Current P/E Ratio (ttm) | 22.7753 |
|---|---|
| Estimated P/E (12/2012) | 16.7175 |
| Earnings Per Share (USD) (ttm) | 1.7800 |
| Est. EPS (USD) (12/2012) | 2.4250 |
| Est. PEG Ratio | 1.2993 |
| Market Cap (M USD) | 2,567.69 |
| Shares Outstanding (M) | 63.34 |
| Enterprise Value (M USD) (ttm) | 2,236.61 |
| Enterprise Value/EBITDA (ttm) | 8.33 |
| Price/Book (mrq) | 7.1120 |
| Price/Sale (ttm) | 3.1175 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 07/13/2012 |
More CBST Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for CBST
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for CBST
Cubist Pharmaceuticals, Inc. is a drug company that discovers, develops, and commercializes novel drugs to treat infections. The Company's lead product is a unique agent with bactericidal activity that addresses the critical need for new antibiotics with potent activity against life threatening infections.
| Kenneth M Bate "Ken"Chairman | Michael Weston Bonney "Mike"President/CEO |
| Robert J PerezExec VP/COO | Steven C Gilman "Steve"Exec VP:Research & Development |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page